Charles River Laboratories International, Inc. (CRL) Set to Announce Quarterly Earnings on Tuesday

Charles River Laboratories International, Inc. (NYSE:CRL) will be releasing its Q416 earnings data on Tuesday, February 14th. Analysts expect Charles River Laboratories International to post earnings of $1.11 per share and revenue of $441.70 million for the quarter. Persons interested in listening to the company’s earnings conference call can do so using this link.

Earnings History for Charles River Laboratories International (NYSE:CRL)

Charles River Laboratories International, Inc. (NYSE:CRL) opened at 83.34 on Monday. The stock has a market capitalization of $3.94 billion, a PE ratio of 28.16 and a beta of 0.99. Charles River Laboratories International, Inc. has a 52-week low of $67.20 and a 52-week high of $89.18. The firm has a 50-day moving average of $79.87 and a 200-day moving average of $79.45.

A number of research firms have issued reports on CRL. Evercore ISI upgraded shares of Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $86.50 target price for the company in a research report on Wednesday, January 4th. Jefferies Group LLC reiterated a “buy” rating and issued a $93.00 target price on shares of Charles River Laboratories International in a research report on Tuesday, December 20th. Bank of America Corporation set a $93.00 target price on shares of Charles River Laboratories International and gave the stock a “buy” rating in a research report on Friday, November 18th. Zacks Investment Research upgraded shares of Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $75.00 target price for the company in a research report on Thursday, November 3rd. Finally, Barclays PLC upgraded shares of Charles River Laboratories International from an “underweight” rating to an “equal weight” rating and increased their target price for the stock from $65.00 to $77.00 in a research report on Wednesday, November 30th. Six equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $84.85.

In related news, Director Stephen D. Chubb sold 4,564 shares of the firm’s stock in a transaction on Friday, December 2nd. The shares were sold at an average price of $71.57, for a total value of $326,645.48. Following the transaction, the director now directly owns 30,849 shares in the company, valued at approximately $2,207,862.93. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider David P. Johst sold 13,950 shares of the firm’s stock in a transaction on Monday, January 30th. The shares were sold at an average price of $78.00, for a total transaction of $1,088,100.00. Following the completion of the transaction, the insider now owns 174,696 shares in the company, valued at $13,626,288. The disclosure for this sale can be found here. Insiders have sold a total of 23,053 shares of company stock worth $1,741,236 in the last 90 days. 2.30% of the stock is owned by insiders.

TRADEMARK VIOLATION WARNING: “Charles River Laboratories International, Inc. (CRL) Set to Announce Quarterly Earnings on Tuesday” was published by sleekmoney and is the property of of sleekmoney. If you are accessing this news story on another website, it was stolen and republished in violation of United States and international copyright and trademark laws. The original version of this news story can be accessed at http://sleekmoney.com/charles-river-laboratories-international-inc-crl-set-to-announce-quarterly-earnings-on-tuesday/1657208.html.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a full service, early-stage contract research company. The Company is engaged in the business of providing the research models required in research and development of new drugs, devices and therapies. The Company operates through three segments: Research Models and Services (RMS), which consists of Research Models and Research Model Services; Discovery and Safety Assessment (DSA), which offers discovery and safety assessment services, both regulated and non-regulated, in which it includes both in vivo and in vitro studies, and Manufacturing Support (Manufacturing), which includes Microbial Solutions, Biologics Testing Solutions and Avian Vaccine Services.

5 Day Chart for NYSE:CRL

This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/charles-river-laboratories-international-inc-crl-set-to-announce-quarterly-earnings-on-tuesday/1657208.html

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *